Obstetrics/Gynecology
RSSArticles
Influenza A Resistant to Oseltamivir
Oseltamivir treatment of children with influenza A virus infection was associated with the selection of resistant mutants in 18%.Pharmacology Watch: The FDA and Merck Fielding Concerns About Vioxx
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.Clinical Briefs
Agents which alter cardiac repolarization have been associated with torsades de pointes.Pharmacology Update: Hydromorphone Extended-Release Capsules (Palladone) (C-II)
The FDA has approved a new formulation of hydromorphone for the management of pain.Better Shoulder Outcomes with Spinal Manipulative Therapy
Adding early manual manipulation of the cervicothoracic spine for shoulder pain or dysfunction disorders, in addition to regular care of information, advice and medications, produced much better recovery at both 12- and 52-weeks post treatments.Hemoglobin A1c: It’s Not Just for Diabetics Anymore
The relative risk for each 1% increase in hemoglobin A1c was 1.3 for CHD, 1.2 for CVD, and 1.2 for all cause mortality.Risk of Community-Acquired Pneumonia and Use of Gastric Acid-Suppressive Drugs
Current use of gastric acid-suppressive therapy was associated with an increased risk of community-acquired pneumonia.Full November 2004 issue in PDF
Clinical Briefs in Primary Care supplement
Special Feature: Chemotherapy Sensitivity/Resistance Assays in Gynecologic Cancer: Are We There Yet?
Over the last few decades, technology has existed to evaluate the cytotoxic effects of single-agent and combination chemotherapy on cancer cell lines derived from an individual patient's tumor specimens. However, investigators and clinicians have been frustrated as the fruit of this technologya reliable and reproducible assay to help them treat their patients with the agent or agents most likely to benefit themhas yet to be proven.